Often described as the “King of Leukemia”, Hagop Kantarjian is one of the most transformative figures in modern hematologic oncology. As Professor and the long-serving leader of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, he helped build the program into a global epicenter of leukemia research and training. Over his career, he has authored more than 2,400 scientific publications, many of which directly changed clinical practice in CML, ALL, AML, and MDS, contributing to the development and approval of more than 20 life-saving therapies. His work has improved—and in many cases revolutionized—outcomes for millions of patients worldwide.
Dr. Kantarjian has mentored hundreds of oncologists who now lead major programs across the globe, extending his impact across generations. He is a co-founder and board secretary of the Society of Hematologic Oncology (SOHO), today one of the world’s fastest-growing professional societies in blood cancer. A fearless advocate for equitable access to cancer care and rational drug pricing, he is among the most influential policy voices in oncology. In 2023, ASCO recognized his extraordinary contributions with its highest scientific honor, the David A. Karnofsky Memorial Award.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
